Based on the evidence, we recommend the use of SGLT2 inhibitors for patients with diabetes complicated with hypertension at stage A and stage B. Furthermore, glucagon‐like peptide‐1 receptor (GLP‐1R) agonists also lead to significant weight loss and BP reduction, which might serve as potential drugs for overweight or obese patients with hypertension.62 Here, SLC5A2 is linked to hypertensive disorder.